Alterity Therapeutics Reports Positive Phase 2 Data for ATH434

TL;DR

ALTERITY THERAPEUTICS (ATHE) posts positive interim Phase 2 data for MSA drug ATH434, hitting primary endpoint.

AI Summary

Alterity Therapeutics Ltd. announced positive interim data from its ATH434-202 Phase 2 clinical trial for Multiple System Atrophy (MSA) on July 17, 2024. The trial met its primary endpoint, demonstrating a statistically significant reduction in alpha-synuclein in cerebrospinal fluid (CSF) in patients treated with ATH434 compared to placebo. The company also reported positive trends in exploratory clinical endpoints.

Why It Matters

This positive interim data suggests ATH434 may be effective in treating MSA, a rare neurodegenerative disease with no approved treatments, potentially offering a new therapeutic option for patients.

Risk Assessment

Risk Level: medium — While the interim data is positive, the trial is ongoing, and further results are needed to confirm efficacy and safety for regulatory approval.

Key Numbers

• Phase 2 — Clinical Trial Phase (Interim data reported for the ATH434-202 trial.)

Key Players & Entities

• Alterity Therapeutics Limited (company) — Registrant
• ATH434-202 (drug_trial) — Phase 2 clinical trial
• ATH434 (drug) — Investigational drug
• Multiple System Atrophy (MSA) (disease) — Target disease
• July 17, 2024 (date) — Date of announcement
• alpha-synuclein (biomarker) — Primary endpoint measured
• cerebrospinal fluid (CSF) (biological_fluid) — Sampled for biomarker analysis

FAQ

Filing Documents

• ea0209552-6k_alterity.htm (6-K) — 13KB
• ea020955201ex99-1_alterity.htm (EX-99.1) — 39KB
• ex99-1_001.jpg (GRAPHIC) — 4KB
• 0001213900-24-061933.txt ( ) — 59KB

From the Filing

OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: July 17, 2024 2

View Full Filing

View this 6-K filing on SEC EDGAR